Skip to Content
Merck
  • ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.

ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.

Scientific reports (2018-09-01)
Francisco Javier Rodríguez-Baena, Silvia Redondo-García, Carlos Peris-Torres, Estefanía Martino-Echarri, Rubén Fernández-Rodríguez, María Del Carmen Plaza-Calonge, Per Anderson, Juan Carlos Rodríguez-Manzaneque
ABSTRACT

Recent advances have emphasized the relevance of studying the extracellular microenvironment given its main contribution to tissue homeostasis and disease. Within this complex scenario, we have studied the extracellular protease ADAMTS1 (a disintegrin and metalloprotease with thrombospondin motif 1), implicated in vascularization and development, with reported anti- and pro-tumorigenic activities. In this work we performed a detailed study of the vasculature and substrates in adult organs of wild type and Adamts1-deficient mice. In addition to the expected alterations of organs like kidney, heart and aorta, we found that the lack of ADAMTS1 differently affects lymphocyte and myeloid populations in the spleen and bone marrow. The study of the substrate versican also revealed its alteration in the absence of the protease. With such premises, we challenged our mice with subcutaneous B16F1 syngeneic tumours and closely evaluated the immune repertoire in the tumours but also in the distant spleen and bone marrow. Our results confirmed a pro-inflammatory landscape in the absence of ADAMTS1, correlating with tumour blockade, supporting its novel role as a modulator of the immune cell response.